Beyond Air, Inc. (XAIR)

Beyond Air, Inc. stock has experienced volatility and a downward trend, decreasing by 86.24% over the last 12 months. In September 2025, the stock increased by 97.68% due to FDA designations and positive expectations related to global distribution deals and an orphan designation. August 2025 saw unpredictable stock movement. In Q2 Fiscal Year 2026, Beyond Air reported a 128% year-over-year revenue increase to $1.8 million and updated its fiscal 2026 revenue guidance to $8–$10 million. The company also secured a $12.0 million promissory note and an equity line up to $20 million. From December 2025 to January 2026, the stock price fluctuated considerably. In the past month (January 2026 - February 2026), the stock price increased by 39.37%. Overall, in the past six months, XAIR has trended down by 58.45%.

While overall demand seasonality is not explicitly stated, the company's U.S. pilot trial for LungFit PRO to treat viral community-acquired pneumonia is planned to extend over two seasons, suggesting seasonal patterns for treatments related to viral lung infections. The increasing demand for the LungFit PH system indicates a growing market, but does not explicitly address seasonality for this product.

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company in the Healthcare sector, focusing on the Medical Devices industry. The company develops the LungFit platform, a nitric oxide generator and delivery system that produces NO from ambient air. Key products include LungFit PH (approved for persistent pulmonary hypertension of the newborn), LungFit PRO (under development for viral lung infections), LungFit GO (in development for at-home treatment of nontuberculous mycobacteria), Ultra-high concentration (UNO) (in Phase 1 clinical trials for treating tumors), and a selective neuronal nitric oxide synthase (nNOS) inhibitor (being developed for neurological conditions and autism spectrum disorder).

Beyond Air, Inc. is headquartered in Garden City, New York, United States. The company is expanding globally, securing distribution deals for LungFit PH in Asian and Central American markets, including Japan and South Korea. They have partnered with consultants to expedite LungFit PH distribution across Europe, South America, Asia Pacific, and the Middle East, with initial progress in the Middle East. International shipments are expected to begin soon, with a significant revenue impact projected in the latter half of fiscal year 2026 and beyond.

Beyond Air, Inc. is known for its commitment to revolutionizing nitric oxide therapy. Positive events impacting its reputation include receiving FDA designations, expanding its global distribution network for LungFit PH, solidifying revenue forecasts, reporting a revenue increase in Q1 with reduced EPS loss in September 2025, acceptance for filing by the FDA of a PMA supplement for the expansion of the LungFit PH label to include cardiac surgery, and achieving MDSAP certification and submitting a PMA supplement for the second-generation LungFit PH in June 2025. No negative events impacting the brand reputation were found.

Beyond Air, Inc. has 30 institutional owners and shareholders, holding 1,577,358 shares. Major institutional shareholders include Alyeska Investment Group, L.P., Balyasny Asset Management Llc, Bleichroeder LP, and Vanguard Group Inc. Individual ownership information is less detailed, but insider transactions by Steven Lisi and Robert Carey show purchases of shares in 2024 and 2025.